Muscle-Derived Progenitor Matrix for Bone Graft Cell Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for tissue augmentation, particularly in non-muscle tissues like bone, face challenges such as low survival rates of myoblasts post-transplantation, migration, phagocytosis, inflammation, scarring, and high costs and complexity in producing cell-matrix compositions.
Innovation Solution
The use of muscle-derived progenitor cells (MDCs) combined with a biologically compatible matrix, such as small intestine submucosa (SIS), which are isolated and enriched to express specific markers, and administered with minimal culture time to ensure long-term survival and integration into bone tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If myoblasts are transplanted into bone tissue for augmentation, then bone formation may be achieved, but the survival rate of transplanted cells is low and they undergo migration and phagocytosis
Solution Approach 1:
The patent uses a biocompatible matrix as an intermediary carrier to deliver muscle-derived progenitor cells to the bone defect site. This matrix protects the cells from migration and phagocytosis while providing a structured environment for cell survival and differentiation into bone tissue.
Solution Approach 2:
The patent employs pre-culture of muscle-derived progenitor cells in specific media conditions before transplantation to enhance their survival capabilities and reduce susceptibility to phagocytosis in the host tissue environment.
2Reliability
If muscle-derived progenitor cells are used for bone augmentation, then long-term survival and integration can be achieved, but the production process becomes complex and costly
Solution Approach 1:
The patent utilizes the patient's own muscle tissue as the source of progenitor cells, eliminating the need for complex immunomatching and reducing rejection risks. The autologous nature of the cells simplifies the production process while ensuring long-term survival and integration.
Solution Approach 2:
The patent demonstrates that muscle-derived progenitor cells can serve multiple functions: they can differentiate into both muscle and bone tissue, making them a universal cell source for treating various musculoskeletal defects without requiring different cell types for different applications.
3Ease of operation
If conventional myoblast transplantation is performed, then cell delivery is achieved, but inflammation and scarring occur at the implant site
Solution Approach 1:
The patent changes the physical and chemical parameters of the cell delivery system by using a biocompatible matrix with specific porosity, degradation rate, and mechanical properties. These parameter optimizations reduce the inflammatory response and scarring while maintaining ease of cell delivery.
Data Source
AI summary
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.